文献速递肾小球疾病遗传性与小管间质肾病

抑制STAT3可减轻Alport综合征小鼠模型的进展性表型

STAT3 inhibition attenuates the progressive phenotypes of Alport syndrome mouse model.
PubMed 文献 · Nephrol Dial Transplant · 2018-01-01

本研究在Col4a5 G5X突变Alport综合征小鼠模型中观察到肾脏及肾小球磷酸化STAT3上调。使用STAT3抑制剂stattic(10 mg/kg腹腔注射,每周三次,持续10周,n=10)治疗可改善蛋白尿、血尿素氮和血清肌酐进行性肾功能异常,并抑制损伤、炎症和纤维化相关基因表达。

要点

  • Alport综合征小鼠肾脏和肾小球中磷酸化STAT3表达上调。
  • Stattic(10 mg/kg腹腔注射,每周三次,持续10周)改善AS小鼠肾功能指标。
  • Stattic抑制肾损伤、炎症和纤维化相关基因表达,并减少肾纤维化。

核心结论

  • 抑制STAT3可显著改善Alport综合征小鼠的肾功能障碍,提示STAT3是AS进展的重要调节因子和潜在治疗靶点。

研究设计与样本

  • 使用Col4a5 G5X突变Alport综合征小鼠模型,通过免疫印迹分析肾脏和肾小球磷酸化STAT3表达。
  • 为阻断STAT3信号,AS小鼠接受STAT3抑制剂stattic(10 mg/kg腹腔注射,每周三次,持续10周,n=10)治疗。

主要发现

  • AS小鼠肾脏和肾小球中磷酸化STAT3表达上调。
  • Stattic治疗改善蛋白尿、血尿素氮和血清肌酐升高等进行性肾功能异常。
  • Stattic显著抑制肾损伤标志物(Lcn2、Kim-1)、促炎细胞因子(Il-6、KC)、促纤维化基因(Tgf-β、Col1a1、α-Sma)和Mmp9的基因表达。
  • Stattic减少肾纤维化,伴随TGF-β蛋白下降和抗纤维化标志物p-Smad1、5、8升高。

临床怎么用

  • 本研究为动物实验,STAT3抑制作为Alport综合征治疗策略尚需进一步临床研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Alport syndrome (AS) is a hereditary, progressive nephritis caused by mutation of type IV collagen. Previous studies have shown that activation of signal transducer and activator of transcription 3 (STAT3) exacerbates other renal diseases, but whether STAT3 activation exacerbates AS pathology is still unknown. Here we aim to investigate the involvement of STAT3 in the progression of AS. METHOD: Phosphorylated STAT3 expression was assessed by immunoblotting analysis of kidneys and glomeruli of an AS mouse model (Col4a5 G5X mutant). To determine the effect of blocking STAT3 signaling, we treated AS mice with the STAT3 inhibitor stattic (10 mg/kg i.p., three times per week for 10 weeks; n = 10). We assessed the renal function [proteinuria, blood urea nitrogen (BUN), serum creatinine] and analyzed the glomerular injury score, fibrosis and inflammatory cell invasion by histological staining. Moreover, we analyzed the gene expression of nephritis-associated molecules. RESULTS: Phosphorylated STAT3 was upregulated in AS kidneys and glomeruli. Treatment with stattic ameliorated the progressive renal dysfunction, such as increased levels of proteinuria, BUN and serum creatinine. Stattic also significantly suppressed the gene expression levels of renal injury markers (Lcn2, Kim-1), pro-inflammatory cytokines (Il-6, KC), pro-fibrotic genes (Tgf-β, Col1a1, α-Sma) and Mmp9. Stattic treatment decreased the renal fibrosis congruently with the decrease of transforming growth factor beta (TGF-β) protein and increase of antifibrosis-associated markers p-Smad1, 5 and 8, which are negative regulators of TGF-β signaling. CONCLUSION: STAT3 inhibition significantly ameliorated the renal dysfunction in AS mice. Our finding identifies STAT3 as an important regulator in AS progression and provides a promising therapeutic target for AS.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Yokota T, Omachi K, Suico MA, et al. STAT3 inhibition attenuates the progressive phenotypes of Alport syndrome mouse model. Nephrol Dial Transplant. 2018. PMID: 28992339. doi:10.1093/ndt/gfx246

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。